Basis of molecular pathology in colorectal carcinogenesis

doi:10.3760/cma.j.issn.1673-422X.2014.05.011

Abstract

Abstract: Colorectal carcinogenesis is the result of accumulation of genetic and epigenetic alters. Gene mutations and changes in DNA methylation patterns, resulted from genomic instability, are the main molecular events in colorectal cancer. Identification of key mutations and methylation phenotypes in genes leading to colorectal cancer progression, and molecular pathology classification and diagnosis are likely to be the prerequisites for individualized and targeted treatment.

Key words: Colorectal neoplasms, Genes, Mutation, Methylation

Jiang Weiguo, Huang Youguang. Basis of molecular pathology in colorectal carcinogenesis[J]. Journal of International Oncology, 2014, 41(5): 353-357.

References

［1］李祯, 生秀杰. 结肠癌转移相关基因1与肿瘤［J］. 国际肿瘤学杂志, 2013, 40(1):15-18. ［2］ Gavin PG, Colangelo LH, Fumagalli D, et al. Mutation profiling and microsatellite instability in stage Ⅱ and Ⅲ colon cancer: an assessment of their prognostic and oxaliplatin predictive value［J］. Clin Cancer Res, 2012, 18(23):6531-6541. ［3］ Lagarde P, Pérot G, Kauffmann A, et al. Mitotic checkpoints and chromosome instability are strong predictors of clinical outcome in gastrointestinal stromal tumors［J］. Clin Cancer Res, 2012, 18(3):826-838. ［4］ Shull AY, Clendenning ML, GhoshalGupta S, et al. Somatic mutations, allele loss, and DNA methylation of the Cub and Sushi Multiple Domains 1 (CSMD1) gene reveals association with early age of diagnosis in colorectal cancer patients［J］. PLoS One, 2013, 8(3):e58731. ［5］ Pagin A, Zerimech F, Leclerc J, et al. Evaluation of a new panel of six mononucleotide repeat markers for the detection of DNA mismatch repairdeficient tumours［J］. Br J Cancer, 2013, 108(10):2079-2087. ［6］ Sinicrope FA, Sargent DJ. Molecular pathways: microsatellite instability in colorectal cancer: prognostic, predictive, and therapeutic implications［J］. Clin Cancer Res, 2012, 18(6):1506-1512. ［7］ Pinheiro M, Ahlquist T, Danielsen SA, et al. Colorectal carcinomas with microsatellite instability display a different pattern of target gene mutations according to large bowel site of origin［J］. BMC Cancer, 2010, 10:587-596. ［8］ Chen W, Yuan L, Cai Y, et al. Identification of chromosomal copy number variations and novel candidate loci in hereditary nonpolyposis colorectal cancer with mismatch repair proficiency［J］. Genomics, 2013, 102(1):27-34. ［9］ Fournier A, Sasai N, Nakao M, et al. The role of methylbinding proteins in chromatin organization and epigenome maintenance［J］. Brief Funct Genomics, 2012, 11(3):251-264. ［10］ Walton EL, Francastel C, Velasco G. Maintenance of DNA methylation: Dnmt3b joins the dance［J］. Epigenetics, 2011, 6(11):1373-1377. ［11］ Bae JM, Kim JH, Cho NY, et al. Prognostic implication of the CpG island methylator phenotype in colorectal cancers depends on tumour location［J］. Br J Cancer, 2013, 109(4):1004-1012. ［12］ Bae JM, Kim JH, Kang GH. Epigenetic alterations in colorectal cancer: the CpG island methylator phenotype［J］. Histol Histopathol, 2013, 28(5):585-595. ［13］ Markowitz SD, Bertagnolli MM. Molecular origins of cancer: Molecular basis of colorectal cancer［J］. N Engl J Med, 2009, 361(25):2449-2460. ［14］ Gay LJ, Mitrou PN, Keen J, et al. Dietary, lifestyle and clinicopathological factors associated with APC mutations and promoter methylation in colorectal cancers from the EPICNorfolk study［J］. J Pathol, 2012, 228(3):405-415. ［15］ Zhang T, Fields JZ, Opdenaker L, et al. Survivininduced AuroraB kinase activation: A mechanism by which APC mutations contribute to increased mitoses during colon cancer development［J］. Am J Pathol, 2010, 177(6):2816-2826. ［16］ Lau T, Chan E, Callow M, et al. A novel tankyrase smallmolecule inhibitor suppresses APC mutationdriven colorectal tumor growth［J］. Cancer Res, 2013, 73(10):3132-3144. ［17］侯庆生, 丁渭, 陈德喜. p53凋亡刺激蛋白2对饥饿诱导的大肠癌HCT116p53+/+细胞凋亡、周期和自噬的影响［J］. 国际肿瘤学杂志, 2013, 40(4):298-302. ［18］ Yang W, Rozan LM, McDonald ER, et al. CARPs are ubiquitin ligases that promote MDM2independent p53 and phosphop53ser20 degradation［J］. J Biol Chem, 2007, 282(5):3273-3281. ［19］ Muller PA, Vousden KH. p53 mutations in cancer［J］. Nat Cell Biol, 2013, 15(1):2-8. ［20］ Pineda M, González S, Lázaro C, et al. Detection of genetic alterations in hereditary colorectal cancer screening［J］. Mutat Res, 2010, 693(1-2):19-31. ［21］ Bellam N, Pasche B. Tgfbeta signaling alterations and colon cancer［J］. Cancer Treat Res, 2010, 155:85-103. ［22］ Lee J, Ballikaya S, Schnig K, et al. Transforming growth factor beta receptor 2 (TGFBR2) changes sialylation in the microsatellite unstable (MSI) Colorectal cancer cell line HCT116［J］. PLoS One, 2013, 8(2):e57074. ［23］ Shima K, Morikawa T, Yamauchi M, et al. TGFBR2 and BAX mononucleotide tract mutations, microsatellite instability, and prognosis in 1072 colorectal cancers［J］. PLoS One, 2011, 6(9):e25062. ［24］ Fleming NI, Jorissen RN, Mouradov D, et al. Eppert K, SMAD2, SMAD3 and SMAD4 mutations in colorectal cancer［J］. Cancer Res, 2013, 73(2):725-735. ［25］ Stankic M, Pavlovic S, Chin Y, et al. TGFβId1 signaling opposes twist1 and promotes metastatic colonization via a mesenchymaltoepithelial transition［J］. Cell Rep, 2013, 5(5):12281242. ［26］ Berlin J. Beyond exon 2—the developing story of RAS mutations in colorectal cancer［J］. N Engl J Med, 2013, 369(11):1059-1060. ［27］ Ogino S, Liao X, Imamura Y, et al. Predictive and prognostic analysis of PIK3CA mutation in stage III colon cancer intergroup trial［J］. J Natl Cancer Inst, 2013, 105(23):1789-1798. ［28］ Mao M, Tian F, Mariadason JM, et al. Resistance to BRAF inhibition in BRAFmutant colon cancer can be overcome with PI3K inhibition or demethylating agents［J］. Clin Cancer Res, 2013, 19(3):657-667. PMID: 23251002 ［29］ Slomovitz BM, Coleman RL. The PI3K/AKT/mTOR pathway as a therapeutic target in endometrial cancer［J］. Clin Cancer Res, 2012, 18(21):5856-5864.

[1]	Guo Zehao, Zhang Junwang. Role of PFDN and its subunits in tumorigenesis and tumor development [J]. Journal of International Oncology, 2024, 51(6): 350-353.
[2]	Zhang Rui, Chu Yanliu. Research progress of colorectal cancer risk assessment models based on FIT and gut microbiota [J]. Journal of International Oncology, 2024, 51(6): 370-375.
[3]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu. Research progress on intestinal flora and non-surgical treatment of the colorectal cancer [J]. Journal of International Oncology, 2024, 51(6): 376-381.
[4]	Wang Junyi, Hong Kaibin, Ji Rongjia, Chen Dachao. Effect of cancer nodules on liver metastases after radical resection of colorectal cancer [J]. Journal of International Oncology, 2024, 51(5): 280-285.
[5]	Sun Guobao, Yang Qian, Zhuang Qingchun, Gao Binbin, Sun Xiaogang, Song Wei, Sha Dan. Research progress on the histopathological growth patterns of colorectal liver metastasis [J]. Journal of International Oncology, 2024, 51(2): 114-118.
[6]	Liu Xiaodi, Su Jianfei, Zhang Jingxian, Wei Xueqin, Jia Yingjie. Research progress of myeloid-derived suppressor cells in tumor angiogenesis [J]. Journal of International Oncology, 2024, 51(1): 50-54.
[7]	Ye Tongtong, Wu Zeyu, Xi Wenyi, Wang Zhiwei, Jiang Xiaochun, Zhao Chenhui. Role of ABRACL in the occurrence and development of malignant tumors [J]. Journal of International Oncology, 2023, 50(9): 544-547.
[8]	Pan Shulan, Liu Chang, He Ping. Effect of fritinib on angiogenesis, tumor growth and IRE1-ASK1-JNK pathway in triple negative breast cancer [J]. Journal of International Oncology, 2023, 50(8): 457-462.
[9]	Liu Debao, Sun Ziwen, Lu Shoutang, Xu Haidong. Expression and clinical significance of ASB6 in colorectal cancer tissues [J]. Journal of International Oncology, 2023, 50(8): 470-474.
[10]	Zhang Yuan, Bai Zhiyu, Li Qi, Feng Qinmei. Current status of research on exosomes in malignancies [J]. Journal of International Oncology, 2023, 50(8): 484-488.
[11]	Li Bin, Zhang Guifang, Zhou Linjing, Yang Xiaodong, He Qiuli, Jia Sisi, Huang Puchao, Liang Jiaxin. Relationships between PIK3CA gene status and clinical features and prognosis in triple-negative breast cancer [J]. Journal of International Oncology, 2023, 50(5): 263-267.
[12]	Chen Zhuo, Tao Jun, Chen Lin, Ke Jing. Value of detection of peripheral blood miR-194 combined with fecal miR-143 in the clinical screening of colorectal cancer [J]. Journal of International Oncology, 2023, 50(5): 268-273.
[13]	Huang Zhen, Zhang Caiyutian, Ke Shaobo, Shi Wei, Zhao Wensi, Chen Yongshun. Construction of postoperative prognosis model for patients with colorectal cancer [J]. Journal of International Oncology, 2023, 50(3): 157-163.
[14]	Xu Liangfu, Li Yuanfei. Research progress on tumor microenvironment and immune combination therapy of MSS colorectal cancer [J]. Journal of International Oncology, 2023, 50(3): 186-190.
[15]	Liu Yujie, Zhao Zhiqiang, Wang Zicheng. Levels and diagnostic value of TOP2A and ERBB2 in peripheral blood mononuclear cells of patients with early colorectal cancer [J]. Journal of International Oncology, 2023, 50(12): 717-722.